| Literature DB >> 26041555 |
Maria-Grazia Pennisi1, Luís Cardoso2, Gad Baneth3, Patrick Bourdeau4, Alek Koutinas5, Guadalupe Miró6, Gaetano Oliva7, Laia Solano-Gallego8.
Abstract
Limited data is available on feline leishmaniosis (FeL) caused by Leishmania infantum worldwide. The LeishVet group presents in this report a review of the current knowledge on FeL, the epidemiological role of the cat in L. infantum infection, clinical manifestations, and recommendations on diagnosis, treatment and monitoring, prognosis and prevention of infection, in order to standardize the management of this disease in cats. The consensus of opinions and recommendations was formulated by combining a comprehensive review of evidence-based studies and case reports, clinical experience and critical consensus discussions. While subclinical feline infections are common in areas endemic for canine leishmaniosis, clinical illness due to L. infantum in cats is rare. The prevalence rates of feline infection with L. infantum in serological or molecular-based surveys range from 0% to more than 60%. Cats are able to infect sand flies and, therefore, they may act as a secondary reservoir, with dogs being the primary natural reservoir. The most common clinical signs and clinicopathological abnormalities compatible with FeL include lymph node enlargement and skin lesions such as ulcerative, exfoliative, crusting or nodular dermatitis (mainly on the head or distal limbs), ocular lesions (mainly uveitis), feline chronic gingivostomatitis syndrome, mucocutaneous ulcerative or nodular lesions, hypergammaglobulinaemia and mild normocytic normochromic anaemia. Clinical illness is frequently associated with impaired immunocompetence, as in case of retroviral coinfections or immunosuppressive therapy. Diagnosis is based on serology, polymerase chain reaction (PCR), cytology, histology, immunohistochemistry (IHC) or culture. If serological testing is negative or low positive in a cat with clinical signs compatible with FeL, the diagnosis of leishmaniosis should not be excluded and additional diagnostic methods (cytology, histology with IHC, PCR, culture) should be employed. The most common treatment used is allopurinol. Meglumine antimoniate has been administered in very few reported cases. Both drugs are administered alone and most cats recover clinically after therapy. Follow-up of treated cats with routine laboratory tests, serology and PCR is essential for prevention of clinical relapses. Specific preventative measures for this infection in cats are currently not available.Entities:
Mesh:
Year: 2015 PMID: 26041555 PMCID: PMC4462189 DOI: 10.1186/s13071-015-0909-z
Source DB: PubMed Journal: Parasit Vectors ISSN: 1756-3305 Impact factor: 3.876
Species of Leishmania identified in cats and geographical areas of description
| Species | Country (area) | Method | Global distribution | Reference |
|---|---|---|---|---|
|
| Brazil (Mato Grosso do Sul state) | ILMA | South America | [ |
|
| Brazil (Belo Horizonte city) | PCR and hybridization | Central and South America | [ |
| Brazil (Rio de Janeiro city) | MLEE | [ | ||
| France (French Guiana) | PCR and sequencing | [ | ||
|
| Iran (Fars and East Azerbaijan provinces) | PCR and MLEE | China, Middle East, Mediterranean basin, and Central and South America | [ |
| Italy (Imperia, Liguria) | PCR-RFLP | [ | ||
| Italy (Messina, Sicily) | MLEE | [ | ||
| Italy (Lipari island, Sicily) | MLEE and PCR-RFLP | [ | ||
| Switzerlanda | PCR and sequencing | [ | ||
| France (Alpes-Maritimes) | MLEE | [ | ||
| Spain (Barcelona) | PCR and sequencing | [ | ||
| Spain (Madrid community) | PCR and sequencing | [ | ||
| Spaina | ILMA | [ | ||
| Spain (Mallorca)b | PCR-RFLP | [ | ||
| Portugal (Lisbon region) | PCR and sequencing | [ | ||
| Portugal (Lisbon and Algarve regions) | PCR and sequencing | [ | ||
| Greece (Thessaly and Macedonia) | PCR and sequencing | [ | ||
| Brazil (Cotia, São Paulo state) | PCR and sequencing | [ | ||
| Brazil (Rio de Janeiro) | PCR and hybridization | [ | ||
| Brazil (Andradina, São Paulo state) | PCR and sequencing | [ | ||
| Brazil (Araçatuba, São Paulo state) | PCR and sequencing | [ | ||
|
| USA (Texas) | MLEE | North and Central America | [ |
| USA (Texas) | PCR and sequencing | [ | ||
|
| Venezuela (Barquisimeto city) | MLEE and ILMA | South America | [ |
aNo data available on the exact origin; bFeral cats; cSubgenus Viannia (species L. braziliensis geographically assumed); d L. braziliensis complex (species L. braziliensis reasonably assumed; Leishmania peruviana species geographically excluded); e L. mexicana complex; ILMA: immunolabelling with monoclonal antibodies; MLEE: multilocus isoenzyme electrophoresis; PCR: polymerase chain reaction; RFLP: restriction fragment length polymorphism
Prevalence of Leishmania infantum infection in cats in the Old World (countries listed in geographical order from East to West)
| Country (area) | No. of cats (type) | Seroprevalence (test) | PCR prevalence (sample) | Combined prevalence of infection | Prevalence of clinical signs in positive cats | Reference |
|---|---|---|---|---|---|---|
| Iran (Fars and East Azerbaijan provinces) | 40 (stray) | 27.5 % (IFAT and DAT) | NA | NA | NA | [ |
| Iran (Fars and East Azerbaijan provinces) | 40 (stray) | NA | 7.5 % (liver and spleen) | 10.0%a | 25.0 % (cutaneous) | [ |
| Israel (Jerusalem) | 104 (mainly stray) | 6.7 % (ELISA) | NA | NA | 14.3%b (cutaneous) | [ |
| Egypt (Ismailia governorate) | 80 (stray) | 3.8 % (IHAT) | NA | NA | NA | [ |
| Egypt (Suez governorate) | 28 (stray) | 3.6 % (IHAT) | NA | NA | NA | [ |
| Egypt (Giza governorate) | 60 (mixed) | 10.0 % (IHAT) | NA | NA | NA | [ |
| Greece (Thessaloniki) | 284 (stray) | 3.9 % (ELISA) | NA | NA | 0.0 % | [ |
| Greece (Thessaloniki) | 389 (stray/feral) | 21.6 % (IFAT) | NA | NA | 19.0 % (compatible) | [ |
| Greece (Macedonia and Thessaly) | 100 (domestic) | 11.0 % (IFAT and ELISA) | 41.0 % (skin, bone marrow, blood and conjunctiva) | 46.0 %c | 39.1 % (cutaneous, ocular or systemic) | [ |
| Albania (Tirana surroundings) | 146 (stray) | 0.7 % (IFAT) | 0.0 % (blood) | 0.7 % | 0.0 % | [ |
| Italy (Sicily) | 93 (mixed) | 59.1 % (IFAT) | NA | NA | 0.0 % (cutaneous) | [ |
| Italy (Catania and Messina provinces, Sicily) | 89 (mixed) | 68.5 % (IFAT) | 60.7 % (blood) | 85.4 % | NAb | [ |
| Italy (Liguria and Tuscany) | 110 (domestic) | 0.9 % (IFAT) | NA | NA | 0.0 % | [ |
| Italy (Abruzzo) | 203 (mixed) | 16.3 % (IFAT) | 45.5 (blood), 100 % (lymph node)d | NA | 66.4 % (heterogeneous) | [ |
| Italy (Ischia island, Campania) | 95 (mixed) | 9.5 % (IFAT) | 5.3 (blood), 0.0 % (bone marrow) | 13.7 % | 0.0 % | [ |
| Italy (Calabria and Sicily) | 431 (mixed) | 6.9 % (IFAT) | 7.8 % (blood), 11.7 % (lymph node), 16.7 % (conjunctival swabs) | 13.9 % | NAe | [ |
| Italy (Greater Milan) | 233 (stray) | 25.3 % (IFAT) | 0.0 % (blood) | 25.3 % | 79.7 % (heterogeneous)b | [ |
| France (Nice surroundings) | 97 (stray) | 12.4 % (WB) | NA | NA | 0.0 % | [ |
| Spain (Barcelona and Girona provinces) | 117 (domestic) | 1.7 % (ELISA) | NA | NA | NA | [ |
| Spain (Aragon) | 50 (domestic) | 42.0 % (DAT) | NA | NA | 100 % (immune dysfunction) | [ |
| Spain (Catalonia and Mallorca island) | 445 (mixed) | 5.3–6.3 % (ELISA)f | NA | NA | NAb | [ |
| Spain (south) | 183 (domestic) | 28.3–60.0 % (IFAT)f | 25.7 % (blood) | 70.6 % | NA | [ |
| Spain (Barcelona) | 100 (domestic) | NA | 3.0 % (blood) | NA | 100 % (ND) | [ |
| Spain (Madrid community) | 233 (domestic) | 1.3–4.3 % (IFAT)f | 0.4 % (blood) | 1.7–4.7%f | 66.7 % (heterogeneous)b | [ |
| Spain (Ibiza island) | 105 (stray/shelter) | 13.2 % (ELISA) | 8.7 % (blood) | 15.4 % | 25.0 % (cutaneous)g | [ |
| Spain (Mallorca island) | 86 (stray/feral) | 15.7 % (WB) | 26.0 % (blood) | 25.6 % | 0.0 % | [ |
| Spain (Madrid community) | 20 (breeding cats) | 15.0 % (IFAT) | NA | NA | 0.0 % | [ |
| Spain (Madrid community) | 680 (mixed) | 3.7 % (IFAT) | 0.6 % (blood) | NA | NAe | [ |
| Spain (Madrid community, Guadalajara and Toledo provinces) | 346 (stray) | 3.2 % (IFAT) | 0.0 % (blood) | 3.2 % | 9.1 % (compatible)b | [ |
| Portugal (Lisbon region) | 23 (stray) | 20.0 % (IFAT) | 30.4 % (blood) | 34.8 % | 0.0 % (compatible) | [ |
| Portugal (northeast) | 316 (domestic) | 2.8 % (ELISA and DAT) | NA | NA | 11.1 % (ND)b | [ |
| Portugal (Lisbon region) | 180 (stray) | 0.6 % (IFAT) | NA | NA | 0.0 % (compatible) | [ |
| Portugal (Lisbon region) | 142 (domestic) | 1.3 % (IFAT) | 20.3 % (blood) | 20.4 % | NA | [ |
| Portugal (North and Centre regions) | 320 (domestic) | NA | 0.3 % (blood) | NA | 0.0%b | [ |
| Portugal (Lisbon and Algarve regions) | 649 (mixed) | NA | 9.9 % (blood) | NA | 27.3 % (compatible)b | [ |
| Portugal (Algarve) | 271 (mixed) | 3.7 % (DAT) | NA | NA | NA | [ |
aPCR results in combination with those from liver and spleen touch smears and cultures; bNo statistical association between clinical status and prevalence of infection/exposure; cNegative results of lymph node, bone marrow, skin and conjunctiva cytology; dPCR performed only for 11 seropositive cats; eStatistical association between clinical status and both seroprevalence and combined prevalence; fDifferent prevalences obtained with different ELISA techniques or IFAT cut off; gStatistical association between clinical status and seroprevalence; DAT: direct agglutination test (cut-off titre: 1:100 or 1:800); ELISA: enzyme-linked immunosorbent assay (different techniques); IFAT: immunofluorescence antibody test (cut-off titre ranging from 1:2 to 1:100); IHAT: indirect haemagglutination test (cut-off titre: 1:32); NA: not assessed/available; ND: clinical signs not described; PCR: polymerase chain reaction; WB: western blot
Parasitological, serological, and clinical results from experimental Leishmania infections in cats
| Cats (n) |
| Inoculum | Route | Sampling | Evidence of infection | Serology | Clinical abnormalities | Reference |
|---|---|---|---|---|---|---|---|---|
| 10 |
| 8 × 108 amastigotes (isolated from a French dog and maintained by serial passages in golden hamsters) | IV | 2 cats necropsied at 1 h PI, and weeks 1, 2, 4 and 8 PI | Parasites in spleen, liver, bone marrow (cytology or culture) and blood culture from 1 to 8 weeks PI | IFAT: highly positive from 1 to 8 weeks PI | None | [ |
| 5 |
| 5 × 107 amastigotes (isolated from a human being in Brazil and maintained by serial passages in golden hamsters) | IV | Cats necropsied at weeks 4 ( | Parasites in spleen, liver and bone marrow (cytology or culture) from week 4 to 16, but not at week 24 (no parasites cultured from blood at any point) | IFAT: highly positive from weeks 2 to 24 (rise to 30-fold at the end of the study) | None | [ |
| 6 |
| 5 × 107 promastigotes ( | ID (thorax) | Pairs of cats necropsies at weeks 4, 16 and 24; blood culture at weeks 2, 4, 8, 12, 16 and 24 | No parasites detected at necropsy (bone marrow, spleen or liver) or blood cultures | IFAT: positive from weeks 2 to 24 (lower than for cats IV inoculated) | None | [ |
| 3 |
| 108 promastigotes (derived from cultures of the splenic tissue from one IV inoculated cat) | ID | Necropsies at 12 weeks PI | Negative cultures of different tissues | ND | None | [ |
| 6 + 6 |
| 106 promastigotes | IC + IV | 2 cats necropsied at months 1 to 6 PI | Negative on blood, bone marrow, liver, spleen, kidney and lymph node cultures and smears | ND | None | [ |
| 13 |
| 107 promastigotes | ID (ear and nose) | Follow-up for 72 weeks ( | Positive parasite cultures from aspirates of a primary ear lesion at week 6 | ELISA: positive at week 2; all cats were seropositive at week 20; after self-healing, 3 cats remained seropositive until the end of the study and none of them had lesion recurrence | Single papules on the ear and nose as early at week 2; regression at about 32 and 40 weeks PI in the ear and nose, respectively; one cat had lesion recurrence on the ear 4 months after self-healing | [ |
| 4 cats necropsied at weeks 4, 12, 16 and 24 | Negative cultures and imprints from liver, spleen and bone marrow |
ELISA: enzyme-linked immunosorbent assay; IC: intracardiac; ID: intradermal; IFAT: immunofluorescence antibody test; IV: intravenous; ND: not done; PI: post-infection
Frequency (%) of clinical manifestations described in a total of 46 case reports and 15 histopathological case descriptions of feline leishmaniosis from European countries (1989–2014)
| Frequency of clinical manifestations (%) | ||
|---|---|---|
| ~50 % | 20–30 % | <10 % |
| Lymph node enlargement | Ocular lesions (mainly uveitis) | Pale mucous membranes |
| Skin and/or mucocutaneous lesions (mainly ulcerative or nodular) | Oral lesions | Hepatomegaly |
| Weight loss | Icterus | |
| Anorexia | Cachexia | |
| Lethargy | Fever | |
| Dehydration | Vomiting | |
| Diarrhea | ||
| Chronic nasal discharge | ||
| Splenomegaly | ||
| Polyuria/polydipsia | ||
| Itching | ||
| Dyspnea | ||
| Wheezing | ||
| Abortion | ||
| Hypothermia | ||
Fig. 1Clinical findings of feline leishmaniosis due to Leishmania infantum: bilateral uveitis with blood clot (hyphema) in the anterior chamber
Fig. 2Clinical findings of feline leishmaniosis due to Leishmania infantum: stomatitis and glossitis involving respectively cheeks and margin of the tongue
Fig. 3Clinical findings of feline leishmaniosis due to Leishmania infantum: nodular conjunctivitis (upper eyelid) and ulcerative dermatitis
Fig. 4Clinical findings of feline leishmaniosis due to Leishmania infantum: ulcerative dermatitis on distal limb
Fig. 5Clinical findings of feline leishmaniosis due to Leishmania infantum: focal alopecia and scales
Fig. 6Clinical findings of feline leishmaniosis due to Leishmania infantum: symmetrical alopecia on pinnae and acral thickening of the margin of left ear
Clinical cases of feline leishmaniosis caused by species other than Leishmania infantum
|
| Geographic location | Signalment | Lesions and outcome | Reference |
|---|---|---|---|---|
|
| Brazil | 2-year-old female | Single, nodular lesion (2 cm in diameter) on the nose and many nodules of different sizes on the ears and digital regions; smears from lesion aspirates with numerous amastigotes. Respiratory failure and euthanasia some days after diagnosis | [ |
|
| Brazil | 4-year-old female | Cutaneous ulcer (0.5 cm in diameter) present for 6 months on the nose, enlargement of the | [ |
| 5-year-old female | Papule on the bridge of the nose and vegetating lesion on the nasal mucosa for 3 months. Good general condition. Outcome not described | |||
| French Guiana | 3 to 5-year-old female | Cutaneous ulcer (1 cm in diameter) on the nose (for ~8 month) and nodules of different sizes on the ears. Outcome not reported | [ | |
|
| USA (Texas) | Immunocompetent long-haired adult male followed up for 7 years | Four large (4–7 mm) and many small nodules initially confined to the left ear; lesions with numerous amastigote forms | [ |
| Two years after a radical pinnectomy, the animal had lesion recurrence at the stump, and lesions later developed on the muzzle and nasal mucosa; treatment was attempted several times, but with no resolution | ||||
| USA (Texas) | 8 domestic cats (5 males and 3 females) aged 1 to 11 years old (median: 3 years) | One or multiple nodules on the pinnae and less commonly on the muzzle and periorbital skin, with variably ulcerated, scaled or smooth surfaces (histology: numerous amastigotes) | [ | |
| Two cats had recurrent cutaneous leishmaniosis: one was treated with allopurinol, but the skin lesions continued to recur despite treatment; in three other cats, excisional biopsy was apparently curative, and lesions did not recur during the follow-up period (2–4 years) | ||||
|
| Venezuela (Lara state) | 4 cats | One cat: nodular lesion (2 cm) on the nose and six smaller nodules on the ears; two cats: single nodules (2–3 cm) on the nose; one cat: single nodule on the nose (2–3 cm) and 3 months afterwards presented with metastatic new lesions on the ears, tail and lower limbs | [ |
Fig. 7Fine-needle aspirate of a reactive lymph node from a cat with feline leishmaniosis due to Leishmania infantum: lymphoid hyperplasia and a macrophage with L. infantum amastigotes (red arrows). May-Grünwald-Giemsa stain, scale bar = 20 μm
Laboratory methods for diagnosis of Leishmania infection in cats
| Method | Principle | Features | Recommendations | References |
|---|---|---|---|---|
| Serology | Detection of specific antibodies by IFAT and ELISA (more frequently used), DAT and WB | Different sensitivities and specificities, partially dependent on the cut-off values; clinical cases may have from low to high positive antibody levels, but the latter are usually diagnostic | Antibodies should be evaluated using techniques validated in cats; parasitological methods should be employed in clinically suspect but seronegative or low positive cats | [ |
| Cytology | Detection of amastigotes in stained tissue smears (ex: lymph node, bone marrow, skin and cornea) | Specific, but time-consuming and requiring expertise | For compatible skin or mucosal lesions, enlarged lymph nodes and other lesions, and for clinically suspected cases if serology is negative or low positive | [ |
| Histology with IHC | Detection of amastigotes in histopathology tissue specimens | Specific, but time-consuming and requiring expertise | [ | |
| IHC is not widely available | ||||
| Culture | Multiplication of promastigotes from tissues | Not suitable for rapid diagnosis and not widely available | For research and species and/or strain identification | [ |
| PCR | Amplification of parasite DNA from tissues and biological fluids, including blood, buffy coat, bone marrow, lymph nodes and conjunctival swabs | More sensitive than cytology or histology with IHC; may allow molecular characterization and quantification of the parasitic load | Preferable to sample more than one tissue, in order to increase sensitivity of detection especially in subclinical infections | [ |
DAT: direct agglutination test; ELISA: enzyme-linked immunosorbent assay; IFAT: immunofluorescence antibody test; IHC: immunohistochemistry; PCR: polymerase chain reaction; WB, western blot
Therapeutic regimens used in cats affected by feline leishmaniosis
| Drug and dosage | Duration | Number of treated cats | References |
|---|---|---|---|
| Allopurinol (10–15 mg/kg/12 h, 20 mg/kg/24 h, 25 mg/cat/12 h, 100 mg/cat/24 h) PO | 6 months - 3 years | 15 | [ |
| Meglumine antimoniate (20–50 mg/kg/24 h SC) | 20–30 days | 1 | [ |
| Meglumine antimoniate (175 mg/cat/48 h IM) | 55 days | 1 | [ |
| Meglumine antimoniate (5 mg/kg/24 h SC) in combination with Ketoconazole (10 mg/kg/24 h PO) | 3 cycles of 4 weeks, 10 days apart | 1 | [ |
| Fluconazole (5 mg/kg/24 h PO) | 60 days | 1a | [ |
| Spiramycin (150.000 IU/kg) and Metrodinazole (25 mg/kg) 24 h PO | 35 days | 1a | [ |
| Itraconazole (50 mg/cat/24 h PO) | 60 days | 1a | [ |
SC: subcutaneous; IM: intamuscular; PO: per os a a same cat was treated with the three different therapeutic regimens at subsequent times